To assess the methodology of the studies providing reference intervals for possible CSF biomarkers [i.e., amyloid peptides Aβ1–42 (Aβ42), total tau (T-tau), and 181-phospo-tau (P-tau)] in AD, we retrieved all available literature published up to May 2019. This evidence concerns the gene MAPT and Alzheimer disease.